BMC Cancer

Table 1 Baseline characteristics of incident SCLC cases

From: Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom

Baseline characteristic	Incident SCLC cases (N = 2938)
Sex	n	%
Male	1524	51.9
Female	1414	48.1
Age (years)
Mean (±SD)	68.45 (68.10–68.80)
50–59	94	3.2
60–69	451	15.4
70–79	972	33.1
80–89	1054	35.9
Smoking^a
Non-smoker	141	4.8
Current	1455	49.5
Former	1299	44.2
Unknown	43	1.5
BMI (kg/m²)^a
15–19	189	6.4
20–24	945	32.2
25–29	926	31.5
≥30	590	20.1
Unknown	288	9.8
Alcohol (units/week)^a
None	18,790	16.5
1–9	47,121	41.4
10–20	14,390	12.6
21–41	4986	4.4
≥42	1820	1.6
Unknown	26,833	23.6
Geographical setting
Urban	1923	65.5
Town	303	10.3
Rural	113	3.8
Unknown	599	20.4
Comorbidities^b
MI	285	9.7
IS	153	5.2
PAD	289	9.8
Heart failure	152	5.2
Hypertension	1256	42.8
Hyperlipidaemia	646	22.0
Dyspepsia	789	26.9
Depression	847	28.8
GERD	531	18.1
Asthma	718	24.4
COPD	739	25.2
Medications^c
Beta2-agonists	1181	40.2
Oral corticosteroids	849	28.9
Inhaled steroids	624	21.2
Antiplatelets	1097	37.3
NSAIDs	810	27.6
Opioids	1604	54.6
PPIs	1125	38.3
H₂RA	232	7.9

^aEver before SCLC diagnosis using the most recent value/status as appropriate
^bEver before SCLC diagnosis
^cIn the year prior to SCLC diagnosis
BMI body mass index, COPD chronic obstructive pulmonary disease, DVT deep vein thrombosis, GERD gastro-oesophageal reflux disease, H₂RA histamine 2 receptor antagonists, IS ischaemic stroke, MI myocardial infarction, NSAID non-steroidal anti-inflammatory drug, PAD peripheral artery disease, PPI proton pump inhibitor, SCLC small-cell lung cancer, SD standard deviation, TIA transient ischaemic attack

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com